Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM

CHEN, SHARON C-A; PERFECT, JOHN; COLOMBO, ARNALDO L; CORNELY, OLIVER A; GROLL, ANDREAS H; SEIDEL, DANILA; ALBUS, KERSTIN; DE ALMEIDA, JOÃO NOBREGA; GARCIA-EFFRON, GUILLERMO; GILROY, NICOLE; LASS-FLÖRL, CORNELIA; OSTROSKY-ZEICHNER, LUIS; PAGANO, LIVIO; PAPP, TAMAS; RAUTEMAA-RICHARDSON, RIINA; SALMANTON-GARCÍA, JON; SPEC, ANDREJ; STEINMANN, JOERG; ARIKAN-AKDAGLI, SEVTAP; ARENZ, DOROTHEE E; SPRUTE, ROSANNE; DURAN-GRAEFF, LUISA; FREIBERGER, TOMAS; GIRMENIA, CORRADO; HARRIS, MICHELLE; KANJ, SOUHA S; ROUDBARY, MARYAM; LORTHOLARY, OLIVIER; MELETIADIS, JOSEPH; SEGAL, ESTHER; TUON, FELIPE FRANCISCO; WIEDERHOLD, NATHAN; BICANIC, TIHANA; CHANDER, JAGDISH; CHEN, YEE-CHUN; HSUEH, PO-REN; IP, MARGARET; MUNOZ, PATRICIA; SPRIET, ISABEL; TEMFACK, ELVIS; THOMPSON, LUIS; TORTORANO, ANNA MARIA; VELEGRAKI, ARISTEA; GOVENDER, NELESH P

LANCET INFECTIOUS DISEASES

ELSEVIER SCIENCE INC

Año: 2021

1473-3099

Uncommon, or rare, yeast infections are on the rise given increasing numbers of patients who areimmunocompromised or seriously ill. The major pathogens include those of the genera Geotrichum, Saprochaete,Magnusiomyces, and Trichosporon (ie, basidiomycetes) and Kodamaea, Malassezia, Pseudozyma (ie, now Moesziomycesor Dirkmeia), Rhodotorula, Saccharomyces, and Sporobolomyces (ie, ascomycetes). A considered approach to thecomplex, multidisciplinary management of infections that are caused by these pathogens is essential to optimisingpatient outcomes; however, management guidelines are either region-specific or require updating. In alignmentwith the One World?One Guideline initiative to incorporate regional differences, experts from diverse geographicalregions analysed publications describing the epidemiology and management of the previously mentioned rareyeasts. This guideline summarises the consensus recommendations with regards to the diagnostic and therapeuticoptions for patients with these rare yeast infections, with the intent of providing practical assistance in clinicaldecision making. Because there is less clinical experience of patients with rare yeast infections and studies on thesepatients were not randomised, nor were groups compared, most recommendations are not robust in their validationbut represent insights by use of expert opinions and in-vitro susceptibility results. In this Review, we report the keyfeatures of the epidemiology, diagnosis, antifungal susceptibility, and treatment outcomes of patients withGeotrichum, Saprochaete, Magnusiomyces, and Trichosporon spp infections.